Review

rabbit anti mouse pim1 (Bioss)

Bioss is a verified supplier

Bioss manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bioss rabbit anti mouse pim1
Rabbit Anti Mouse Pim1, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti mouse pim1/product/Bioss
Average 94 stars, based on 5 article reviews

rabbit anti mouse pim1 - by Bioz Stars, 2026-05

94/100 stars

Images

Image Search Results

a Representative western blots showing protein expression levels of S100A8 and -A9 in the indicated human TNBC cell lines and non-tumorigenic human mammary epithelial cells (HMEC). b Schematic representation of the ELISA screen performed in this study. MDA-MB-468 cells were treated with 30 targeted anticancer agents at their respective half-maximal inhibitory concentration (IC50) (Supplementary Table ) or 10 μM, whichever was lower. c Results from the ELISA screen described in Fig. 2b ( n = 3). d Representative western blots showing the effects of the indicated pan-PIM kinase inhibitors on S100A8 expression in the indicated TNBC cell lines (72 h). e Representative western blots showing expression of PIM1, -2, -3, S100A8, and -A9 in the cells transiently transfected with Cas9 proteins and the indicated PIM -specific, synthetic multi-guide sgRNA or a nonspecific control sgRNA. The resulting cells represent heterogenous KO pools and not single-cell clones. f Relative S100A8/A9 secretion (72 h) in Cas9/ PIM -specific, sgRNA-transfected MDA-MB-468 cells shown in Fig. 2e ( n = 3). g Relative mRNA expression of S100A8 (left) and - A9 (right), as determined by qPCR, in Cas9/ PIM -specific, sgRNA-transfected MDA-MB-468 cells shown in Fig. 2E ( n = 3). h Representative western blots showing the effects of exogenously introduced PIM1 on S100A8 and -A9 expression in the cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs. i The effects of exogenously introduced PIM1 on relative S100A8/A9 secretion in MDA-MB-468 cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs ( n = 3). j The effects of exogenously introduced PIM1 on relative mRNA expression of S100A8 (left) and - A9 (right), as determined by qPCR, in MDA-MB-468 cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs ( n = 3). Throughout this figure, actin serves as a loading control. Error bars represent means +/- the standard error of the mean. A two-tailed t -test was used to calculate p- values; ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS: not significant. In (c), only the drugs that achieved p < 0.001 are indicated.

Journal: Communications Medicine

Article Title: S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models

doi: 10.1038/s43856-024-00444-8

Figure Lengend Snippet: a Representative western blots showing protein expression levels of S100A8 and -A9 in the indicated human TNBC cell lines and non-tumorigenic human mammary epithelial cells (HMEC). b Schematic representation of the ELISA screen performed in this study. MDA-MB-468 cells were treated with 30 targeted anticancer agents at their respective half-maximal inhibitory concentration (IC50) (Supplementary Table ) or 10 μM, whichever was lower. c Results from the ELISA screen described in Fig. 2b ( n = 3). d Representative western blots showing the effects of the indicated pan-PIM kinase inhibitors on S100A8 expression in the indicated TNBC cell lines (72 h). e Representative western blots showing expression of PIM1, -2, -3, S100A8, and -A9 in the cells transiently transfected with Cas9 proteins and the indicated PIM -specific, synthetic multi-guide sgRNA or a nonspecific control sgRNA. The resulting cells represent heterogenous KO pools and not single-cell clones. f Relative S100A8/A9 secretion (72 h) in Cas9/ PIM -specific, sgRNA-transfected MDA-MB-468 cells shown in Fig. 2e ( n = 3). g Relative mRNA expression of S100A8 (left) and - A9 (right), as determined by qPCR, in Cas9/ PIM -specific, sgRNA-transfected MDA-MB-468 cells shown in Fig. 2E ( n = 3). h Representative western blots showing the effects of exogenously introduced PIM1 on S100A8 and -A9 expression in the cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs. i The effects of exogenously introduced PIM1 on relative S100A8/A9 secretion in MDA-MB-468 cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs ( n = 3). j The effects of exogenously introduced PIM1 on relative mRNA expression of S100A8 (left) and - A9 (right), as determined by qPCR, in MDA-MB-468 cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs ( n = 3). Throughout this figure, actin serves as a loading control. Error bars represent means +/- the standard error of the mean. A two-tailed t -test was used to calculate p- values; ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS: not significant. In (c), only the drugs that achieved p < 0.001 are indicated.

Article Snippet: The antibodies used for western blotting in this study and their working concentrations are: βActin (clone C4, Santa Cruz Biotechnology, sc-47778 HRP, 1:10000), human PIM1 (clone ZP003, Abcam, ab54503, 1:500), mouse PIM1 (clone C93F2, Cell Signaling Technology, 3247, 1:750), human PIM2 (clone D1D2, Cell Signaling Technology, 4730, 1:500), mouse PIM2 (clone EPR6987, Abcam, ab129057, 1:10000), PIM3 (clone D17C9, Cell Signaling Technology, 4165, 1:500), human S100A8 (clone C-10, Santa Cruz Biotechnology, sc-48352 HRP, 1:500), mouse S100A8 (R&D Systems, AF3059, 1:500), human S100A9 (clone 6B4, Millipore Sigma, MABF854, 1;500), mouse S100A9 (clone 372510, R&D Systems, MAB2065, 1:500), STAT3 (clone 124H6, Cell Signaling Technology, 9139, 1:1000), STAT3 pS727 (Cell Signaling Technology, 9134, 1;1000), C/EBPβ (clone H-7, Santa Cruz Biotechnology, sc-7962 HRP, 1:200), C/EBPβ pT235 (Cell Signaling Technology, 3084, 1:1000), c-MYC (clone Y69, Abcam, ab32072, 1:2000), PPARG (clone C26H12, Cell Signaling Technology, 2435, 1:1000), Ubiquitin (clone P4D1, Cell Signaling Technology, 14049, 1:1000), CD45 (clone EPR20033, Abcam, ab208022, 1:1000).

Techniques: Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Transfection, Control, Clone Assay, Two Tailed Test

a Venn diagram showing the transcription factors (TFs) most reproducibly identified as responsible for S100A8 and - A9 expression across four public datasets (ENCODE 2015, ChEA 2016, TF Perturbations/Expression, and TRUST TF 2019) in the Enrichr database (Supplementary Data ). b Gene co-expression analysis of S100A8 or - A9 and their candidate TFs in the TCGA breast and breast cancer METABRIC datasets. c Representative western blots showing protein expression levels of the candidate TFs identified in ( a ) and PIM1, -2, and -3 in the indicated TNBC cell lines and HMEC cells. d Representative western blots showing the effects of knocking down the candidate TFs identified in ( a ) on S100A8 and -A9 expression in the indicated TNBC cell lines. Two siRNA sequences per gene were used as indicated. e Representative western blots showing the effects of GDC-0339 alone or in the presence of MG-132 (1 μM) on the levels of total or T235-phosphorylated C/EBPβ. f Representative western blots showing the effects of GDC-0339 on the abundance of ubiquitinated C/EBPβ. IP: immunoprecipitation; WB: western blotting. g Representative western blots showing the effects of GDC-0339 on the levels of total or S727-phosphorylated STAT3. h Representative western blots showing the levels of total and phosphorylated C/EBPβ and STAT3 in the cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs, in the presence or absence of exogenously introduced PIM1. i Schematic representation of the proposed signaling mechanisms by which PIM controls S100A8 and -A9 expression. Throughout this figure, GDC-0339 was used at 5 μM. Actin serves as a loading control. The numbers in red indicate relative protein expression.

Journal: Communications Medicine

Article Title: S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models

doi: 10.1038/s43856-024-00444-8

Figure Lengend Snippet: a Venn diagram showing the transcription factors (TFs) most reproducibly identified as responsible for S100A8 and - A9 expression across four public datasets (ENCODE 2015, ChEA 2016, TF Perturbations/Expression, and TRUST TF 2019) in the Enrichr database (Supplementary Data ). b Gene co-expression analysis of S100A8 or - A9 and their candidate TFs in the TCGA breast and breast cancer METABRIC datasets. c Representative western blots showing protein expression levels of the candidate TFs identified in ( a ) and PIM1, -2, and -3 in the indicated TNBC cell lines and HMEC cells. d Representative western blots showing the effects of knocking down the candidate TFs identified in ( a ) on S100A8 and -A9 expression in the indicated TNBC cell lines. Two siRNA sequences per gene were used as indicated. e Representative western blots showing the effects of GDC-0339 alone or in the presence of MG-132 (1 μM) on the levels of total or T235-phosphorylated C/EBPβ. f Representative western blots showing the effects of GDC-0339 on the abundance of ubiquitinated C/EBPβ. IP: immunoprecipitation; WB: western blotting. g Representative western blots showing the effects of GDC-0339 on the levels of total or S727-phosphorylated STAT3. h Representative western blots showing the levels of total and phosphorylated C/EBPβ and STAT3 in the cells transiently transfected with Cas9/ PIM1,2,3 -specific sgRNAs, in the presence or absence of exogenously introduced PIM1. i Schematic representation of the proposed signaling mechanisms by which PIM controls S100A8 and -A9 expression. Throughout this figure, GDC-0339 was used at 5 μM. Actin serves as a loading control. The numbers in red indicate relative protein expression.

Techniques: Expressing, Western Blot, Immunoprecipitation, Transfection, Control

a Schematic representation of the flow of the experiments and downstream analyses conducted. b Representative western blots showing protein abundance of S100A8, -A9, PIM1, -2, and -3 in the indicated tumors (two samples per line) or non-tumor tissues. #This panel is a composite of two sides of identical western blot. c Flow analysis showing PD-1/PD-L1-positivity in the indicated cell populations in size-controlled tumors (500 mm 3 ; n = 4 for Py8119, n = 5 for D2A1-M1 and -M2). d Representative western blots showing the effects of the indicated pan-PIM inhibitors (5 μM) on the total abundance or phosphorylation levels of the indicated proteins in CD11b + Gr1+ myeloid cells isolated from D2A1-M1 tumor-bearing mice. e , f Growth of indicated tumors in mice treated with the indicated drugs or drug combinations for 2 weeks ( n = 5 per treatment group). Linear regression analysis was used to calculate p- values. g Growth of Py8119 tumors in mice treated with GDC-0339 plus an anti-PD-1 antibody ( n = 5 per treatment group). h The effects of the indicated drugs or drug combinations on the indicated cytotoxic immune response-related parameters (scoring system) adopted by the NanoString IO360 TM platform. Box plots show the 25 th , 50 th (median), and 75 th percentiles. These parameters have not been designed to generate data indicative of statistical significance. TILs, tumor-infiltrating lymphocytes. i Heat map representation of the effects of the indicated drug treatment on the relative expression of the indicated cytotoxic immune response-related genes. The individual tumor samples represented in this heat map correspond to those in Fig. 4h. Throughout this figure, GDC-0339 was used at 100 mg/kg/dose, and anti-PD-1/PD-L1 antibodies were used at 12 mg/kg/dose in vivo. Error bars represent means +/- the standard error of the mean. Unless otherwise indicated, a two-tailed t -test was used to calculate p- values; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS: not significant. Actin serves as a loading control.

Journal: Communications Medicine

Article Title: S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models

doi: 10.1038/s43856-024-00444-8

Figure Lengend Snippet: a Schematic representation of the flow of the experiments and downstream analyses conducted. b Representative western blots showing protein abundance of S100A8, -A9, PIM1, -2, and -3 in the indicated tumors (two samples per line) or non-tumor tissues. #This panel is a composite of two sides of identical western blot. c Flow analysis showing PD-1/PD-L1-positivity in the indicated cell populations in size-controlled tumors (500 mm 3 ; n = 4 for Py8119, n = 5 for D2A1-M1 and -M2). d Representative western blots showing the effects of the indicated pan-PIM inhibitors (5 μM) on the total abundance or phosphorylation levels of the indicated proteins in CD11b + Gr1+ myeloid cells isolated from D2A1-M1 tumor-bearing mice. e , f Growth of indicated tumors in mice treated with the indicated drugs or drug combinations for 2 weeks ( n = 5 per treatment group). Linear regression analysis was used to calculate p- values. g Growth of Py8119 tumors in mice treated with GDC-0339 plus an anti-PD-1 antibody ( n = 5 per treatment group). h The effects of the indicated drugs or drug combinations on the indicated cytotoxic immune response-related parameters (scoring system) adopted by the NanoString IO360 TM platform. Box plots show the 25 th , 50 th (median), and 75 th percentiles. These parameters have not been designed to generate data indicative of statistical significance. TILs, tumor-infiltrating lymphocytes. i Heat map representation of the effects of the indicated drug treatment on the relative expression of the indicated cytotoxic immune response-related genes. The individual tumor samples represented in this heat map correspond to those in Fig. 4h. Throughout this figure, GDC-0339 was used at 100 mg/kg/dose, and anti-PD-1/PD-L1 antibodies were used at 12 mg/kg/dose in vivo. Error bars represent means +/- the standard error of the mean. Unless otherwise indicated, a two-tailed t -test was used to calculate p- values; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. NS: not significant. Actin serves as a loading control.

Techniques: Western Blot, Quantitative Proteomics, Phospho-proteomics, Isolation, Expressing, In Vivo, Two Tailed Test, Control

Review

Structured Review

Images

Similar Products

Image Search Results